ICHR
Ichor Holdings, Ltd.
ICHR's outlook is improving despite an expensive valuation.
PLTR
Palantir Technologies Inc.
PLTR has the edge over ICHR overall, supported by stronger valuation and stronger fundamentals.
ICHR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Weak | |
| Strong |
ICHR's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
PLTR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
PLTR's revenue, profitability, cash flow and balance sheet are all currently strong.
ICHR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $37.07 | — |
| Cheap | 13x | $0.63 | -98% |
| Fair | 20x | $1.01 | -97% |
| Expensive | 42x | $2.11 | -94% |
| Current | 741x | $37.07 | — |
Historical ranges are pointers, not guarantees.
ICHR's PE is in its expensive range at 741x. If earnings grow as analysts expect, today's price would be 12x next year's earnings, in its cheap range.
PLTR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 75x | $172 | — |
| Current | 120x | $172 | — |
| Cheap | 165x | $236 | +37% |
| Fair | 251x | $359 | +109% |
| Expensive | 452x | $646 | +277% |
Historical ranges are pointers, not guarantees.
PLTR has the edge over ICHR in the historical PE scenario, which offers more potential upside but is not a forecast.
ICHR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect strong earnings and revenue growth for ICHR, with profitability improving.
PLTR Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| Moderate |
Analysts expect strong earnings and revenue growth for PLTR, with profitability improving.
ICHR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.17 | +6237% |
| Q3 2026 | $0.05 | +$1.24 |
| Q2 2026 | -$1.17 | -$0.57 |
| Q1 2026 | -$1.48 | -$1.01 |
| Q4 2025 | -$1.54 | -$0.90 |
| Q3 2025 | -$1.19 | -$0.26 |
| Q2 2025 | -$0.60 | +$0.61 |
| Q1 2025 | -$0.47 | +$1.30 |
| Q4 2024 | -$0.64 | +$0.83 |
ICHR has returned to profit: it earned $0.05 per share over the past year, after losing money the year before.
PLTR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.30 | +61% |
| Q3 2026 | $1.43 | +240% |
| Q2 2026 | $1.17 | +290% |
| Q1 2026 | $0.89 | +287% |
| Q4 2025 | $0.63 | +232% |
| Q3 2025 | $0.42 | +110% |
| Q2 2025 | $0.30 | +76% |
| Q1 2025 | $0.23 | +92% |
| Q4 2024 | $0.19 | +111% |
PLTR has the edge over ICHR on earnings, with more consistent year-over-year improvement.
ICHR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $328.7M | +37% |
| Q2 2026 | $294.8M | +23% |
| Q1 2026 | $256.1M | +4.7% |
| Q4 2025 | $223.6M | -4.2% |
| Q3 2025 | $239.3M | +13% |
| Q2 2025 | $240.3M | +18% |
| Q1 2025 | $244.5M | +21% |
| Q4 2024 | $233.3M | +15% |
ICHR's revenue is growing: $329M last quarter, up 37% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 6.9% | +15 points |
| Q2 2026 | 2.4% | +4.4 points |
| Q1 2026 | 0.8% | +1.3 points |
| Q4 2025 | -6.2% | -5.7 points |
| Q3 2025 | -8.1% | -7.9 points |
| Q2 2025 | -2% | -0.9 points |
| Q1 2025 | -0.5% | +1.4 points |
| Q4 2024 | -0.5% | +3.4 points |
ICHR's operating margin was 6.9% last quarter, up 15 points from the same quarter a year ago.
PLTR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.3B | +96% |
| Q2 2026 | $1.9B | +93% |
| Q1 2026 | $1.6B | +85% |
| Q4 2025 | $1.4B | +70% |
| Q3 2025 | $1.2B | +63% |
| Q2 2025 | $1B | +48% |
| Q1 2025 | $883.9M | +39% |
| Q4 2024 | $827.5M | +36% |
PLTR has the edge over ICHR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 47% | +14 points |
| Q2 2026 | 47% | +20 points |
| Q1 2026 | 46% | +26 points |
| Q4 2025 | 41% | +40 points |
| Q3 2025 | 33% | +18 points |
| Q2 2025 | 27% | +11 points |
| Q1 2025 | 20% | +7.2 points |
| Q4 2024 | 1.3% | -9.5 points |
PLTR has the edge over ICHR on profitability, with a higher operating margin.
ICHR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$39.5M | -1983% |
| Q2 2026 | -$23.6M | -$8.8M |
| Q1 2026 | -$10M | -2113% |
| Q4 2025 | $5.9M | +$12.8M |
| Q3 2025 | $2.1M | -3.3% |
| Q2 2025 | -$14.8M | -201% |
| Q1 2025 | $496K | +58% |
| Q4 2024 | -$6.9M | -119% |
ICHR's free cash flow was −$67M over the past year, against −$19M the year before.
PLTR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.2B | +139% |
| Q2 2026 | $1.2B | +126% |
| Q1 2026 | $891.8M | +193% |
| Q4 2025 | $764M | +67% |
| Q3 2025 | $500.9M | +20% |
| Q2 2025 | $531.6M | +276% |
| Q1 2025 | $304.1M | +140% |
| Q4 2024 | $457.2M | +54% |
PLTR has the edge over ICHR on cash generation, producing positive trailing cash flow while its opponent burns cash.
ICHR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.1% | +1.9M shares |
| 1 year | +11% | +3.8M shares |
| 3 years | +30% | +8.9M shares |
| 5 years | +31% | +9.1M shares |
| Available history | +67% | +15.4M shares |
ICHR has 38M diluted shares, up 11% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
PLTR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +5.2M shares |
| 1 year | +0.1% | +2.9M shares |
| 3 years | +11% | +248M shares |
| 5 years | +31% | +610M shares |
| Available history | +184% | +1.7B shares |
PLTR has the edge over ICHR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $19.2M |
| Q3 2025 | $19.2M |
| Q2 2025 | $18.6M |
| Q1 2025 | $18M |
| Q4 2024 | $18.6M |
| Q3 2024 | $18.9M |
| Q2 2024 | $17.7M |
| Q1 2024 | $9M |
ICHR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.9x | Net Cash |
| Q2 2026 | -16.3x | Net Cash |
| Q3 2025 | 6.5x | High |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | 0.7x | Very low |
| Q4 2024 | 0.9x | Very low |
| Q3 2024 | 0.8x | Very low |
| Q2 2024 | 1.1x | Healthy |
ICHR has the edge over PLTR on leverage, with a lower net debt burden relative to earnings.
PLTR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.1x | Net Cash |
| Q2 2026 | -0.8x | Net Cash |
| Q1 2026 | -1.1x | Net Cash |
| Q4 2025 | -1.0x | Net Cash |
| Q3 2025 | -1.9x | Net Cash |
| Q2 2025 | -1.6x | Net Cash |
| Q1 2025 | -2.3x | Net Cash |
| Q4 2024 | -6.1x | Net Cash |
PLTR has more cash than debt.
ICHR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.9 | Neutral |
| Stochastic | 10.0 | Oversold |
ICHR's weekly RSI is 38 (neutral) and its Stochastic is 10 (oversold).
PLTR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.4 | Neutral |
| Stochastic | 47.4 | Neutral |
PLTR's weekly RSI is 51 (neutral) and its Stochastic is 47 (neutral).
ICHR PE vs Technology Sector
| Metric | ICHR | Sector median | Relative |
|---|---|---|---|
| PE | 741x | 28x | 2,561% above |
| PE % | 100 | 35 | 65 pts above |
ICHR is trading at 741x earnings, a 2561% premium to the Technology sector's median of 28x.
PLTR PE vs Technology Sector
| Metric | PLTR | Sector median | Relative |
|---|---|---|---|
| PE | 120x | 28x | 331% above |
| PE % | 1 | 38 | 37 pts below |
PLTR has the edge over ICHR on valuation relative to its sector.
ICHR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $46.0 | 19% below |
| 20 week MA | $61.7 | 40% below |
| 50 week MA | $54.6 | 32% below |
| 100 week MA | $38.3 | 3.1% below |
| 200 week MA | $35.8 | 3.5% above |
ICHR has fallen below most of its moving averages, though it's still 3.5% above its 200-week average.
PLTR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $185.8 | 7.6% below |
| 20 week MA | $167.6 | 2.4% above |
| 50 week MA | $157.1 | 9.2% above |
| 100 week MA | $143.8 | 19% above |
| 200 week MA | $83.3 | 106% above |
PLTR has the edge over ICHR on trend strength, trading above more of its moving averages.
ICHR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $33.9 | $30.5 | -10% |
| 2021 | $30.5 | $45.5 | +49% |
| 2022 | $45.5 | $26.2 | -42% |
| 2023 | $26.2 | $33.6 | +28% |
| 2024 | $33.6 | $31.4 | -6.7% |
| 2025 | $31.4 | $19.0 | -40% |
| 2026 YTD | $19.0 | $37.1 | +96% |
ICHR has the edge over PLTR on returns for 2026, with the stronger performance.
PLTR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.20 | $27.8 | +202% |
| 2021 | $27.8 | $18.9 | -32% |
| 2022 | $18.9 | $6.29 | -67% |
| 2023 | $6.29 | $17.2 | +173% |
| 2024 | $17.2 | $79.1 | +361% |
| 2025 | $79.1 | $188.7 | +139% |
| 2026 YTD | $188.7 | $171.6 | -9.1% |
PLTR's yearly returns have swung widely, from +361% in 2024 to −67% in 2022. It's down 9.1% so far in 2026.